−290KRW
−9.70 BKRW
9.59 BKRW
26.17 M
About INTRON BIO
Sector
Headquarters
Seongnam-si
Employees (FY)
77
Website
Founded
1999
ISIN
KR7048530000
FIGI
BBG001BGCLW4
iNtRON Biotechnology, Inc. engages in the development of super-bacteria treatment, antibiotics alternatives, bio new drug, molecular diagnostics and artificial blood. Its products include anti-bacterial agents, identification kits, research reagents and kits. The company was founded on January 18, 1999 and is headquartered in Seongnam-si, South Korea.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 048530 is 6850.00 KRW — it has decreased by 1.15% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange INTRON BIO stocks are traded under the ticker 048530.
INTRON BIO is going to release the next earnings report on May 14, 2024. Keep track of upcoming events with our Earnings Calendar.
048530 earnings for the last quarter are 294.76 KRW whereas the estimation was −8.33 KRW which accounts for 3.64 K% surprise. Estimated earnings for the next quarter are 92.62 KRW. See more details about INTRON BIO earnings.
INTRON BIO revenue for the last quarter amounts to 23.36 B KRW despite the estimated figure of 4.46 B KRW. In the next quarter revenue is expected to reach 7.01 B KRW.
Yes, you can track INTRON BIO financials in yearly and quarterly reports right on TradingView.
Like other stocks, 048530 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INTRON BIO stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 77.00 employees. See our rating of the largest employees — is INTRON BIO on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INTRON BIO EBITDA is −1.42 B KRW, and current EBITDA margin is −14.33%. See more stats in INTRON BIO financial statements.